Teva was founded in Jerusalem in 1901 as a small drug wholesaler that distributed imported medicines. The company was called Salomon, Levin and Elstein. Mass immigration followed with the founding of the State in 1948, resulted in rapid growth of the local drug market. In 1951, the company went public through an initial public offering on the Tel Aviv Stock Exchange. (Source: Datamonitor)
Teva manufactures generic pharmaceutical drugs, proprietary branded pharmaceuticals, biopharmaceuticals, veterinary pharmaceutical products and active pharmaceutical ingredients. It
is one of the leading generic drug companies in the world and the leading generic drug manufacturer in the US. Teva has direct operations in over 50 markets in the Americas, Israel, Europe and Asia. Its operational infrastructure includes 36 pharmaceutical manufacturing sites, 16 API sites and 17generic R&D centers and 18 active pharmaceutical ingredients (API) manufacturing sites around the world. The company primarily operates through two segments: pharmaceuticals and active pharmaceutical ingredients (API).
• Teva produces generic drugs in all major therapeutics and steriles in a variety of dosage forms, from tablets and capsules to ointments, creams and liquids.
• In addition, Teva manufactures innovative drugs in niche markets where it has a relative advantage in research and development.
Active Pharmaceutical Ingredients (API)
• Teva competitively distributes its API to manufacturers worldwide as well as supports its own pharmaceutical production. These activities, which comprise the core businesses of the company, account for 90% of Teva's total sales.
The TOWS analysis provides us the Threats, Opportunities, Weaknesses and the Strengths of TEVA Pharmaceuticals. The TOWS gives us a better understanding of the external and internal factors of the company. It shows where the company needs to...